Cannabidiol in neurological and neoplastic diseases: Latest developments on the molecular mechanism of action

As the major nonpsychotropic constituent of Cannabis sativa, cannabidiol (CBD) is regarded as one of the most promising therapeutic agents due to its proven effectiveness in clinical trials for many human diseases. Due to the urgent need for more efficient pharmacological treatments for several chronic diseases, in this review, we discuss the potential beneficial effects of CBD for Alzheimers disease, epilepsy, multiple sclerosis, and neurological cancers. Due to its wide range of pharmacological activities (e.g., antioxidant, anti-inflammatory, and neuroprotective properties), CBD is considered a multimodal drug for the treatment of a range of neurodegenerative disorders, and various cancer types, including neoplasms of the neural system. The different mechanisms of action of CBD are here disclosed, together with recent progress in the use of this cannabis-derived constituent as a new therapeutic approach. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.Institute of Human Genetics, Polish Academy of Sciences by the internal grant for the implementation of a single scientific activity and by the National Centre for Research and Development by the grant ONKOKAN, INNOMED/I/11/NCBR/2014